We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-18.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$161M
AUM Growth
-$49.3M
Cap. Flow
-$8.81M
Cap. Flow %
-5.46%
Top 10 Hldgs %
56.91%
Holding
57
New
6
Increased
7
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.65M
2
GILD icon
Gilead Sciences
GILD
+$8.6M
3
BIIB icon
Biogen
BIIB
+$5.49M
4
AMGN icon
Amgen
AMGN
+$4.68M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.21M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$11.7M
2
ILMN icon
Illumina
ILMN
+$5.73M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$5.67M
4
AERI
Aerie Pharmaceuticals
AERI
+$5.17M
5
PBYI icon
Puma Biotechnology
PBYI
+$5.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$12.7M 7.88%
254,500
+54,500
+27% +$3.54M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$139B
$11.7M 7.28%
90,122
+22,400
+33% +$3.88M
CELG
3
DELISTED
Celgene Corp
CELG
$11.4M 7.05%
225,522
-28,000
-11% -$2.07M
GILD icon
4
Gilead Sciences
GILD
$185B
$10.5M 6.5%
213,284
+123,000
+136% +$8.6M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$83.1B
$9.19M 5.7%
31,330
– –
EXEL icon
6
Exelixis
EXEL
$13.7B
$9.11M 5.65%
589,534
-115,000
-16% -$2.05M
ILMN icon
7
Illumina
ILMN
$34.3B
$7.92M 4.91%
34,541
-18,504
-35% -$5.73M
NBIX icon
8
Neurocrine Biosciences
NBIX
$15.8B
$7.05M 4.38%
125,800
+90,300
+254% +$8.65M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$12.6B
$6.17M 3.83%
92,284
-5,000
-5% -$476K
LGND icon
10
Ligand Pharmaceuticals
LGND
$5.68B
$6M 3.72%
90,249
+34,144
+61% +$3.64M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$5.63M 3.5%
73,641
-8,000
-10% -$946K
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$4.95M 3.07%
319,444
-2,992
-0.9% -$60.1K
HALO icon
13
Halozyme
HALO
$12.1B
$4.58M 2.84%
398,633
-30,000
-7% -$479K
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
$4.37M 2.71%
585,930
– –
BIIB icon
15
Biogen
BIIB
$32.7B
$4.06M 2.52%
+17,200
New +$5.49M
AMGN icon
16
Amgen
AMGN
$236B
$3.67M 2.28%
+24,000
New +$4.68M
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$5.13B
$3.58M 2.22%
282,065
+217,065
+334% +$4.21M
RDUS
18
DELISTED
Radius Health, Inc.
RDUS
$3.42M 2.12%
264,211
+245,412
+1,305% +$4.13M
SHPG
19
DELISTED
Shire pic
SHPG
$3.42M 2.12%
25,000
– –
ABMD
20
DELISTED
Abiomed Inc
ABMD
$2.99M 1.85%
11,700
-1,500
-11% -$521K
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$2.66M 1.65%
93,000
-17,000
-15% -$696K
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$401M
$2.39M 1.48%
+43,000
New +$3.3M
XENT
23
DELISTED
Intersect ENT, Inc
XENT
$2.12M 1.32%
96,000
-16,000
-14% -$469K
ALNY icon
24
Alnylam Pharmaceuticals
ALNY
$31.6B
$1.94M 1.2%
33,800
-19,000
-36% -$1.46M
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
$1.89M 1.17%
42,500
– –
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2018 Portfolio in Review

As of Q4 2018, International Biotechnology Trust held 57 positions worth $161M, down 23% from $210M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust withdrew a net $8.81M in Q4 2018, closing 12 positions and reducing 18 holdings. Its most notable exit was Adamas Pharmaceuticals, an estimated $5.67M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $4.06M.

  • International Biotechnology Trust's largest Q4 2018 buy was Biogen: 17,200 shares worth $4.06M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q4 2018, an estimated $8.65M increase.
  • International Biotechnology Trust's biggest Q4 2018 reduction was Array Biopharma Inc, cutting an estimated $11.7M.
  • International Biotechnology Trust fully exited Adamas Pharmaceuticals in Q4 2018, selling an estimated $5.67M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $161M portfolio in Q4 2018.
  • International Biotechnology Trust opened 6 new positions and closed 12 in Q4 2018.
  • International Biotechnology Trust's portfolio value fell 23% quarter-over-quarter to $161M.

Based on International Biotechnology Trust's 13F filing for Q4 2018, filed 14 Feb 2019.